# Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

> **NCT02953509** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 178 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT02953509
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-21
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-03-25
- **Target enrollment:** 178 (ACTUAL)
- **Why stopped:** Study terminated early due to the magrolimab program discontinuation.
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953509, "Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02953509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*